{"pmid":32479856,"title":"SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention.","text":["SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new viral disease that has gained global attention owing to its ability to provoke community and health-care-associated outbreaks of severe infections in human populations. The virus poses serious challenges to clinical management because there are still no approved anti- SARS-CoV-2 drugs available. In this mini-review, we summarize the much updated published reports that demonstrate the mechanism of SARS-CoV-2 entry into host cells, and discuss the availability and development of attractive host-based therapeutic options for SARS-CoV-2 infections.","Biochimie","Mahmoud, Ismail Sami","Jarrar, Yazun Bashir","Alshaer, Walhan","Ismail, Said","32479856"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new viral disease that has gained global attention owing to its ability to provoke community and health-care-associated outbreaks of severe infections in human populations. The virus poses serious challenges to clinical management because there are still no approved anti- SARS-CoV-2 drugs available. In this mini-review, we summarize the much updated published reports that demonstrate the mechanism of SARS-CoV-2 entry into host cells, and discuss the availability and development of attractive host-based therapeutic options for SARS-CoV-2 infections."],"journal":"Biochimie","authors":["Mahmoud, Ismail Sami","Jarrar, Yazun Bashir","Alshaer, Walhan","Ismail, Said"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479856","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.biochi.2020.05.012","keywords":["ace2","drugs","entry","proteases","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668437835119591424,"score":9.490897,"similar":[{"pmid":32142651,"pmcid":"PMC7102627","title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","text":["SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.","Cell","Hoffmann, Markus","Kleine-Weber, Hannah","Schroeder, Simon","Kruger, Nadine","Herrler, Tanja","Erichsen, Sandra","Schiergens, Tobias S","Herrler, Georg","Wu, Nai-Huei","Nitsche, Andreas","Muller, Marcel A","Drosten, Christian","Pohlmann, Stefan","32142651"],"abstract":["The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention."],"journal":"Cell","authors":["Hoffmann, Markus","Kleine-Weber, Hannah","Schroeder, Simon","Kruger, Nadine","Herrler, Tanja","Erichsen, Sandra","Schiergens, Tobias S","Herrler, Georg","Wu, Nai-Huei","Nitsche, Andreas","Muller, Marcel A","Drosten, Christian","Pohlmann, Stefan"],"date":"2020-03-07T11:00:00Z","year":2020,"_id":"32142651","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.cell.2020.02.052","keywords":["ace2","covid-19","sars-cov-2","tmprss2","coronavirus","entry","neutralization","priming","spike"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Serine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490692173825,"score":223.76678},{"pmid":32094589,"pmcid":"PMC7095430","title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses.","text":["Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses.","Over the past 20 years, several coronaviruses have crossed the species barrier into humans, causing outbreaks of severe, and often fatal, respiratory illness. Since SARS-CoV was first identified in animal markets, global viromics projects have discovered thousands of coronavirus sequences in diverse animals and geographic regions. Unfortunately, there are few tools available to functionally test these viruses for their ability to infect humans, which has severely hampered efforts to predict the next zoonotic viral outbreak. Here, we developed an approach to rapidly screen lineage B betacoronaviruses, such as SARS-CoV and the recent SARS-CoV-2, for receptor usage and their ability to infect cell types from different species. We show that host protease processing during viral entry is a significant barrier for several lineage B viruses and that bypassing this barrier allows several lineage B viruses to enter human cells through an unknown receptor. We also demonstrate how different lineage B viruses can recombine to gain entry into human cells, and confirm that human ACE2 is the receptor for the recently emerging SARS-CoV-2.","Nat Microbiol","Letko, Michael","Marzi, Andrea","Munster, Vincent","32094589"],"abstract":["Over the past 20 years, several coronaviruses have crossed the species barrier into humans, causing outbreaks of severe, and often fatal, respiratory illness. Since SARS-CoV was first identified in animal markets, global viromics projects have discovered thousands of coronavirus sequences in diverse animals and geographic regions. Unfortunately, there are few tools available to functionally test these viruses for their ability to infect humans, which has severely hampered efforts to predict the next zoonotic viral outbreak. Here, we developed an approach to rapidly screen lineage B betacoronaviruses, such as SARS-CoV and the recent SARS-CoV-2, for receptor usage and their ability to infect cell types from different species. We show that host protease processing during viral entry is a significant barrier for several lineage B viruses and that bypassing this barrier allows several lineage B viruses to enter human cells through an unknown receptor. We also demonstrate how different lineage B viruses can recombine to gain entry into human cells, and confirm that human ACE2 is the receptor for the recently emerging SARS-CoV-2."],"journal":"Nat Microbiol","authors":["Letko, Michael","Marzi, Andrea","Munster, Vincent"],"date":"2020-02-26T11:00:00Z","year":2020,"_id":"32094589","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1038/s41564-020-0688-y","topics":["Mechanism"],"weight":1,"_version_":1666138490803322880,"score":165.54012},{"pmid":32373994,"title":"Could host cell receptor alteration prevent SARS-CoV-2 viral entry? - Hype or hope.","text":["Could host cell receptor alteration prevent SARS-CoV-2 viral entry? - Hype or hope.","Cell-surface receptors are the inviters of many potent pathogens that can adjust to any kind of circumstance for their existence. Many of these organisms are highly resistant to the currently existing drugs and mutate to new strains with high levels of pathogenesis, posing life-threatening consequences. Owing to such concerns, antiviral strategies are being assessed based on host cell receptor targeting. Many natural compounds with a tendency to strip off the cell surface receptors are under evaluation. Compounds that are non-toxic, patient friendly, and yield a quick output are essential for the current scenario. Drugs targeting the cell surface receptors should, therefore, be developed and standardized for the effective management of SARS-CoV-2 viral infection.","Eur Rev Med Pharmacol Sci","Paulpandi, M","Kavithaa, K","Asaikkutty, A","Balachandar, V","Ayyadurai, N","Arul, N","32373994"],"abstract":["Cell-surface receptors are the inviters of many potent pathogens that can adjust to any kind of circumstance for their existence. Many of these organisms are highly resistant to the currently existing drugs and mutate to new strains with high levels of pathogenesis, posing life-threatening consequences. Owing to such concerns, antiviral strategies are being assessed based on host cell receptor targeting. Many natural compounds with a tendency to strip off the cell surface receptors are under evaluation. Compounds that are non-toxic, patient friendly, and yield a quick output are essential for the current scenario. Drugs targeting the cell surface receptors should, therefore, be developed and standardized for the effective management of SARS-CoV-2 viral infection."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Paulpandi, M","Kavithaa, K","Asaikkutty, A","Balachandar, V","Ayyadurai, N","Arul, N"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32373994","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.26355/eurrev_202004_21040","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496494993408,"score":163.95259},{"pmid":32362314,"pmcid":"PMC7194065","title":"A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells.","text":["A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells.","The pandemic coronavirus SARS-CoV-2 threatens public health worldwide. The viral spike protein mediates SARS-CoV-2 entry into host cells and harbors a S1/S2 cleavage site containing multiple arginine residues (multibasic) not found in closely related animal coronaviruses. However, the role of this multibasic cleavage site in SARS-CoV-2 infection is unknown. Here, we report that the cellular protease furin cleaves the spike protein at the S1/S2 site and that cleavage is essential for S-protein-mediated cell-cell fusion and entry into human lung cells. Moreover, optimizing the S1/S2 site increased cell-cell, but not virus-cell, fusion, suggesting that the corresponding viral variants might exhibit increased cell-cell spread and potentially altered virulence. Our results suggest that acquisition of a S1/S2 multibasic cleavage site was essential for SARS-CoV-2 infection of humans and identify furin as a potential target for therapeutic intervention.","Mol Cell","Hoffmann, Markus","Kleine-Weber, Hannah","Pohlmann, Stefan","32362314"],"abstract":["The pandemic coronavirus SARS-CoV-2 threatens public health worldwide. The viral spike protein mediates SARS-CoV-2 entry into host cells and harbors a S1/S2 cleavage site containing multiple arginine residues (multibasic) not found in closely related animal coronaviruses. However, the role of this multibasic cleavage site in SARS-CoV-2 infection is unknown. Here, we report that the cellular protease furin cleaves the spike protein at the S1/S2 site and that cleavage is essential for S-protein-mediated cell-cell fusion and entry into human lung cells. Moreover, optimizing the S1/S2 site increased cell-cell, but not virus-cell, fusion, suggesting that the corresponding viral variants might exhibit increased cell-cell spread and potentially altered virulence. Our results suggest that acquisition of a S1/S2 multibasic cleavage site was essential for SARS-CoV-2 infection of humans and identify furin as a potential target for therapeutic intervention."],"journal":"Mol Cell","authors":["Hoffmann, Markus","Kleine-Weber, Hannah","Pohlmann, Stefan"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32362314","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.molcel.2020.04.022","keywords":["covid-19","s1/s2","sars-cov-2","tmprss2","cleavage","entry","furin","membrane fusion","spike"],"e_drugs":["Arginine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496066125824,"score":155.6603},{"pmid":32408336,"title":"Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.","text":["Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.","A novel coronavirus was recently discovered and termed SARS-CoV-2. Human infection can cause coronavirus disease 2019 (COVID-19), which has been rapidly spreading around the globe(1,2). SARS-CoV-2 shows some similarities to other coronaviruses. However, treatment options and a cellular understanding of SARS-CoV-2 infection are lacking. Here we identify the host cell pathways modulated by SARS-CoV-2 infection and show that inhibition of these pathways prevent viral replication in human cells. We established a human cell culture model for infection with SARS-CoV-2 clinical isolate. Employing this system, we determined the SARS-CoV-2 infection profile by translatome(3) and proteome proteomics at different times after infection. These analyses revealed that SARS-CoV-2 reshapes central cellular pathways, such as translation, splicing, carbon metabolism and nucleic acid metabolism. Small molecule inhibitors targeting these pathways prevented viral replication in cells. Our results reveal the cellular infection profile of SARS-CoV-2 and led to the identification of drugs inhibiting viral replication. We anticipate our results to guide efforts to understand the molecular mechanisms underlying host cell modulation upon SARS-CoV-2 infection. Furthermore, our findings provide insight for the development of therapy options for COVID-19.","Nature","Bojkova, Denisa","Klann, Kevin","Koch, Benjamin","Widera, Marek","Krause, David","Ciesek, Sandra","Cinatl, Jindrich","Munch, Christian","32408336"],"abstract":["A novel coronavirus was recently discovered and termed SARS-CoV-2. Human infection can cause coronavirus disease 2019 (COVID-19), which has been rapidly spreading around the globe(1,2). SARS-CoV-2 shows some similarities to other coronaviruses. However, treatment options and a cellular understanding of SARS-CoV-2 infection are lacking. Here we identify the host cell pathways modulated by SARS-CoV-2 infection and show that inhibition of these pathways prevent viral replication in human cells. We established a human cell culture model for infection with SARS-CoV-2 clinical isolate. Employing this system, we determined the SARS-CoV-2 infection profile by translatome(3) and proteome proteomics at different times after infection. These analyses revealed that SARS-CoV-2 reshapes central cellular pathways, such as translation, splicing, carbon metabolism and nucleic acid metabolism. Small molecule inhibitors targeting these pathways prevented viral replication in cells. Our results reveal the cellular infection profile of SARS-CoV-2 and led to the identification of drugs inhibiting viral replication. We anticipate our results to guide efforts to understand the molecular mechanisms underlying host cell modulation upon SARS-CoV-2 infection. Furthermore, our findings provide insight for the development of therapy options for COVID-19."],"journal":"Nature","authors":["Bojkova, Denisa","Klann, Kevin","Koch, Benjamin","Widera, Marek","Krause, David","Ciesek, Sandra","Cinatl, Jindrich","Munch, Christian"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32408336","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41586-020-2332-7","e_drugs":["Carbon"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666950579728941057,"score":148.81157}]}